Key Highlights
- Shares of Travere Therapeutics (TVTX) climbed 44% following regulatory clearance for FILSPARI in treating FSGS
- FILSPARI represents the inaugural FDA-sanctioned therapy specifically for focal segmental glomerulosclerosis
- The drug’s authorization extends to adult patients and pediatric cases aged 8 years and above who don’t exhibit nephrotic syndrome
- Travere projects a potential U.S. patient base exceeding 30,000 individuals
- Wall Street firm Guggenheim elevated its valuation forecast for TVTX shares to $54, up from the previous $49 benchmark, reaffirming positive sentiment
Shares of Travere Therapeutics (TVTX) experienced a dramatic 44% surge during Tuesday’s trading after federal regulators authorized FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis — a condition affecting the kidneys that previously had zero approved pharmaceutical interventions.
Travere Therapeutics, Inc., TVTX
The regulatory greenlight encompasses both adult populations and younger patients starting at age 8 who are diagnosed with FSGS but haven’t developed nephrotic syndrome. FILSPARI now stands alone as the sole FDA-sanctioned medication option available for this patient group.
This regulatory victory represents FILSPARI’s second approved indication within the rare kidney disease space, joining its existing authorization for treating IgA nephropathy.
According to company projections, the eligible patient population across the United States exceeds 30,000 individuals with FSGS who satisfy the treatment parameters — specifically those not presenting all three simultaneous indicators of nephrotic syndrome.
Clinical Trial Results That Drove Approval
The regulatory decision stemmed from findings in the Phase 3 DUPLEX Study, characterized as the most extensive interventional clinical investigation ever conducted in the FSGS patient population.
Participants receiving FILSPARI demonstrated a 46% decrease in proteinuria levels measured from initial baseline through the 108-week endpoint. In contrast, patients administered the reference medication, irbesartan at maximum dosing, experienced a 30% reduction.
When examining the subset of participants specifically without nephrotic syndrome indicators, FILSPARI achieved a 48% proteinuria reduction compared to the 27% observed with irbesartan treatment.
Additionally, FILSPARI-treated individuals within this cohort exhibited favorable effects on estimated glomerular filtration rate (eGFR), demonstrating a positive treatment differential of 1.1 mL/min/1.73 m² when measured at the 108-week mark.
The therapeutic agent displayed a tolerability and safety profile that matched irbesartan across both mature and younger patient demographics — a favorable outcome that should facilitate market adoption.
Wall Street’s Response
Guggenheim’s equity analyst Vamil Divan increased his valuation projection for TVTX shares to $54 from the prior $49 target while maintaining his Buy recommendation in response to the regulatory news.
Divan emphasized that the finalized prescribing label exceeded market expectations, highlighting that the authorized patient population proved more expansive than investment community consensus had anticipated.
Crucially, the approved label encompasses both primary and secondary classifications of FSGS — extending beyond merely the primary and genetic variants that financial analysts and company leadership had previously modeled as the core addressable market.
This expanded indication scope creates a substantially larger revenue opportunity than many market observers had factored into their valuations.
TipRanks references an additional analyst maintaining a Buy stance with a $47 valuation target on the equity, while the platform’s technical sentiment indicator also registers a Buy signal.
Following Tuesday’s substantial price movement, TVTX’s total market capitalization reached approximately $2.67 billion.
The FDA’s approval announcement came on April 13, 2026, with the resulting stock price reaction unfolding throughout Tuesday’s market hours.
